New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 24, 2014
09:06 EDTLGNDLigand price target raised to $91 from $78 at Summer Street
Summer Street raised its price target for Ligand shares to $91 following the company's Q4 results and 2014 outlook. It keeps a Buy rating on the stock.
News For LGND From The Last 14 Days
Check below for free stories on LGND the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 15, 2014
09:31 EDTLGNDLigand, Avion Pharmaceuticals sign Captisol license agreement
Subscribe for More Information
August 14, 2014
08:12 EDTLGNDLigand signs multi-program Captisol license agreement with Avion Pharmaceuticals
Subscribe for More Information
August 12, 2014
07:44 EDTLGNDMarinus Pharmaceuticals enters into agreement with CyDex Pharmaceuticals
Marinus Pharmaceuticals (MRNS) announced that it has entered into an agreement with CyDex Pharmaceuticals, a wholly owned subsidiary of Ligand Pharmaceutical (LGND), for the clinical use of Captisol, a patent protected, uniquely modified cyclodextrin, whose chemical structure was designed to improve solubility, stability, bioavailability and dosing of active pharmaceutical ingredients. Marinus intends to evaluate optimizing its intravenous dose form of ganaxolone with Captisol.
August 11, 2014
16:11 EDTLGNDLigand announces $200M share repurchase plan
Subscribe for More Information
16:11 EDTLGNDLigand files to sell $225M of convertible senior notes due 2019
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use